

Lieve Brochez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/529045/publications.pdf>

Version: 2024-02-01

95
papers

3,119
citations

126708

33
h-index

168136

53
g-index

100
all docs

100
docs citations

100
times ranked

5457
citing authors

#	ARTICLE	IF	CITATIONS
1	The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. <i>European Journal of Cancer</i> , 2017, 76, 167-182.	1.3	234
2	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. <i>Cell Death and Differentiation</i> , 2014, 21, 1250-1261.	5.0	195
3	Cancer risk in immune-mediated inflammatory diseases (IMID). <i>Molecular Cancer</i> , 2013, 12, 98.	7.9	104
4	IDO Expression in Cancer: Different Compartment, Different Functionality?. <i>Frontiers in Immunology</i> , 2020, 11, 531491.	2.2	104
5	Chronic and Invasive Fungal Infections in a Family with CARD9 Deficiency. <i>Journal of Clinical Immunology</i> , 2016, 36, 204-209.	2.0	98
6	Characterization of the <i>in vivo</i> immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. <i>Oncotarget</i> , 2015, 4, e982382.	2.1	95
7	Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. <i>European Journal of Dermatology</i> , 2010, 20, 425-433.	0.3	93
8	Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. <i>European Journal of Cancer</i> , 2012, 48, 2004-2011.	1.3	92
9	Dysplastic Nevi. <i>New England Journal of Medicine</i> , 2003, 349, 2233-2240.	13.9	90
10	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2019, 75, 707-711.	0.9	89
11	EGFR in melanoma: clinical significance and potential therapeutic target. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 492-502.	0.7	77
12	miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. <i>International Journal of Oncology</i> , 2013, 42, 1443-1451.	1.4	76
13	Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. <i>European Journal of Cancer</i> , 2017, 86, 358-363.	1.3	72
14	Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 705-720.	2.4	68
15	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. <i>Current Opinion in Oncology</i> , 2019, 31, 54-64.	1.1	66
16	Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?. <i>British Journal of Dermatology</i> , 2014, 171, 987-995.	1.4	63
17	New insights in segmental vitiligo: case report and review of theories. <i>British Journal of Dermatology</i> , 2012, 166, 240-246.	1.4	61
18	Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening. <i>British Journal of Dermatology</i> , 2016, 174, 1258-1265.	1.4	56

#	ARTICLE	IF	CITATIONS
19	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 9.	1.8	54
20	Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review. <i>Case Reports in Dermatology</i> , 2018, 10, 190-197.	0.3	54
21	Total-Body Examination vs Lesion-Directed Skin Cancer Screening. <i>JAMA Dermatology</i> , 2016, 152, 27.	2.0	51
22	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. <i>Cancer Research</i> , 2020, 80, 2983-2995.	0.4	51
23	Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas. <i>Cell Reports</i> , 2020, 33, 108552.	2.9	50
24	Rosettes and other white shiny structures in polarized dermoscopy: histological correlate and optical explanation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 311-313.	1.3	47
25	The role of VEGF-C staining in predicting regional metastasis in melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 257-265.	1.4	46
26	A CARD9 Founder Mutation Disrupts NF- κ B Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation. <i>Frontiers in Immunology</i> , 2018, 9, 2366.	2.2	46
27	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 828-835.	0.4	46
28	Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 334-344.	1.5	45
29	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2589-2598.	2.0	44
30	Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 741-746.	1.3	39
31	Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. <i>Endocrine</i> , 2014, 47, 878-883.	1.1	37
32	In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 57-65.	1.5	36
33	Long non-coding RNAs in cutaneous melanoma: clinical perspectives. <i>Oncotarget</i> , 2017, 8, 43470-43480.	0.8	35
34	Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure. <i>Preventive Medicine</i> , 2016, 93, 177-182.	1.6	34
35	The distribution pattern of segmental vitiligo: clues for somatic mosaicism. <i>British Journal of Dermatology</i> , 2013, 168, 56-64.	1.4	33
36	The role of RhoC in growth and metastatic capacity of melanoma. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 629-636.	0.7	31

#	ARTICLE	IF	CITATIONS
37	Prognostic value and clinical significance of halo naevi regarding vitiligo. <i>British Journal of Dermatology</i> , 2011, 164, 743-749.	1.4	31
38	Different phenotypes of segmental vitiligo based on a clinical observational study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 673-678.	1.3	31
39	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. <i>Neoplasia</i> , 2018, 20, 218-225.	2.3	31
40	A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 507-511.	1.3	30
41	Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 906-915.	0.4	30
42	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 150.	1.8	26
43	Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. <i>Nature Communications</i> , 2018, 9, 2921.	5.8	26
44	Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. <i>Oncotarget</i> , 2018, 9, 25216-25224.	0.8	26
45	Clinical significance of Koebner phenomenon in vitiligo. <i>British Journal of Dermatology</i> , 2012, 167, 1017-1024.	1.4	25
46	Clinical significance of the expression of c-Ski and SnoN, possible mediators in TGF- β 2 resistance, in primary cutaneous melanoma. <i>Journal of Dermatological Science</i> , 2009, 53, 26-33.	1.0	23
47	Skin Cancer Detection Using Infrared Thermography: Measurement Setup, Procedure and Equipment. <i>Sensors</i> , 2022, 22, 3327.	2.1	22
48	A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 21.	1.8	21
49	Cost-effectiveness and Budget Effect Analysis of a Population-Based Skin Cancer Screening. <i>JAMA Dermatology</i> , 2017, 153, 147.	2.0	21
50	P-cadherin counteracts myosin II-B function: implications in melanoma progression. <i>Molecular Cancer</i> , 2010, 9, 255.	7.9	19
51	Incidence of scabies in Belgium. <i>Epidemiology and Infection</i> , 2008, 136, 395-398.	1.0	18
52	Halo naevi with associated vitiligo-like depigmentations: pathogenetic hypothesis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 755-761.	1.3	18
53	The melanoma burden in Belgium; premature morbidity and mortality make melanoma a considerable health problem. <i>Melanoma Research</i> , 1999, 9, 614-618.	0.6	17
54	A short dermoscopy training increases diagnostic performance in both inexperienced and experienced dermatologists. <i>Australasian Journal of Dermatology</i> , 2015, 56, 52-55.	0.4	17

#	ARTICLE	IF	CITATIONS
55	Systemic immune changes associated with adjuvant interferon- β -therapy in stage III melanoma patients. <i>Melanoma Research</i> , 2015, 25, 357-361.	0.6	13
56	High-Resolution 18F-FDG PET/CT for Assessing Three-Dimensional Intraoperative Margins Status in Malignancies of the Head and Neck, a Proof-of-Concept. <i>Journal of Clinical Medicine</i> , 2021, 10, 3737.	1.0	13
57	The haptoglobin phenotype influences the risk of cutaneous squamous cell carcinoma in kidney transplant patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 566-571.	1.3	12
58	Efficacy of Products to Remove Eggs of <i>Pediculus humanus capitis</i> (Phthiraptera: Pediculidae) From the Human Hair. <i>Journal of Medical Entomology</i> , 2014, 51, 400-407.	0.9	12
59	Association of haptoglobin phenotypes with the development of Kaposi's sarcoma in HIV patients. <i>Archives of Dermatological Research</i> , 2011, 303, 763-769.	1.1	10
60	Comparison of Ex Vivo and In Vivo Dermoscopy in Dermatopathologic Evaluation of Skin Tumors. <i>JAMA Dermatology</i> , 2016, 152, 312.	2.0	10
61	Enhanced visualization of blood and pigment in multispectral skin dermoscopy. <i>Skin Research and Technology</i> , 2020, 26, 708-712.	0.8	10
62	Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. <i>BMC Cancer</i> , 2021, 21, 514.	1.1	10
63	Pathologic Evaluation of Skin Tumors With Ex Vivo Dermoscopy With Derm Dotting. <i>JAMA Dermatology</i> , 2017, 153, 154.	2.0	9
64	Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFN- γ -Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 736498.	2.2	8
65	Value of Dermoscopy in a Population-Based Screening Sample by Dermatologists. <i>Dermatology Practical and Conceptual</i> , 2019, 9, 200-206.	0.5	7
66	Recommendations for skin cancer consultation and surgery during COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1876-1878.	1.3	6
67	Dermatological side effects of current and upcoming targeted therapies in oncology. <i>Acta Clinica Belgica</i> , 2011, 66, 97-103.	0.5	6
68	Lesion-directed screening to optimize skin cancer detection in dermatology practice: an observational study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1309-1314.	1.3	5
69	Immune mediated mechanisms of melanocyte destruction. <i>Oncolmmunology</i> , 2012, 1, 526-528.	2.1	4
70	Charting Extracellular Transcriptomes in the Human Biofluid RNA Atlas. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
71	Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting is appropriate?. <i>British Journal of Dermatology</i> , 2022, 187, 244-245.	1.4	4
72	Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 438.	1.1	3

#	ARTICLE	IF	CITATIONS
73	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. <i>Cancers</i> , 2021, 13, 2630.	1.7	3
74	Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: a cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
75	Haptoglobin polymorphism and the risk of actinic keratoses and cutaneous squamous cell carcinoma: A case-control study. <i>Journal of Dermatology</i> , 2019, 46, 274-275.	0.6	2
76	Hypomelanoses Associated with Melanocytic Neoplasia. , 0, , 705-724.		2
77	Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 789473.	2.2	2
78	OC-0682: Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 127, S357-S358.	0.3	1
79	26915 Steps towards trustworthy AI: Detecting unsupported lesions. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, AB26.	0.6	1
80	Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2017, 35, e21006-e21006.	0.8	1
81	Dynamic Infrared Thermography (DIRT) in Biomedical Applications: DIEP Flap Breast Reconstruction and Skin Cancer. <i>Engineering Proceedings</i> , 2021, 8, 3.	0.4	1
82	P032. Indoleamine 2,3 dioxygenase. <i>Melanoma Research</i> , 2011, 21, e34.	0.6	0
83	P069. The haptoglobin phenotype influences the risk of cutaneous squamous cell carcinoma in kidney transplant patients. <i>Melanoma Research</i> , 2011, 21, e55.	0.6	0
84	Phase I trial of stereotactic body radiotherapy with concurrent fixed dose ipilimumab in metastatic melanoma: Dose limiting toxicity and abscopal effect. <i>Annals of Oncology</i> , 2015, 26, viii5.	0.6	0
85	Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation. <i>Annals of Oncology</i> , 2016, 27, vi388.	0.6	0
86	Chemoprevention of basal cell carcinoma: reply from authors. <i>British Journal of Dermatology</i> , 2016, , .	1.4	0
87	Chemoprevention of basal cell carcinoma: reply from authors. <i>British Journal of Dermatology</i> , 2016, 175, 1404-1405.	1.4	0
88	OC-0017: Combined High Dose Radiation and Ipilimumab in Metastatic Melanoma, a Phase I Dose Escalation Trial. <i>Radiotherapy and Oncology</i> , 2017, 123, S5.	0.3	0
89	Successful strategy to treat a solitary cystic melanoma brain metastasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e216-e217.	1.3	0
90	Three-dimensional margin assessment in head and neck malignancies using a submillimetric 18F-FDG PET/CT, results of an ongoing clinical trial. <i>Oral Oncology</i> , 2021, 118, 5.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
92	Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.. Journal of Clinical Oncology, 2019, 37, 422-422.	0.8	0
93	Abstract PR15: Charting extracellular transcriptomes in The Human Biofluid RNA Atlas. , 2020, , .		0
94	The value of measuring uncertainty in neural networks in dermoscopy. Journal of the American Academy of Dermatology, 2022, , .	0.6	0
95	Superficial granulomatous pyoderma with ocular involvement. European Journal of Dermatology, 2010, 20, 648-9.	0.3	0